Want to see TSE:INNO full AI Analyst Report?
INNO Stock Chart & Stats
C$2.70
C$0.25(9.26%)
At close: 4:00 PM EDT
C$2.70
C$0.25(9.26%)
Day’s Range― - ―
52-Week RangeC$2.18 - C$21.00
Previous CloseN/A
Volume100.00
Average Volume (3M)920.00
Market Cap
C$13.27M
Enterprise ValueC$4.95M
Total Cash (Recent Filing)C$6.68M
Total Debt (Recent Filing)C$1.42M
Price to Earnings (P/E)―
Beta-0.63
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cannabinoid-focused Drug DeliveryInnoCan's strategic focus on cannabinoid therapeutics and proprietary long-acting/controlled-release delivery technology creates a durable niche. This specialization supports differentiated R&D, potential intellectual property barriers and cross-market opportunities (human and veterinary) that can sustain competitive advantage over months.
High Gross Margin ProfileA ~90% gross margin indicates highly scalable product economics: once fixed R&D and SG&A are controlled, incremental revenue converts strongly to profit. This structural margin buffer improves chances of achieving sustainable profitability over several quarters as operating expenses normalize or revenues recover.
Moderate Leverage / Meaningful Equity BaseA debt-to-equity around 0.27 and a tangible equity base (~5.2M) provide financial flexibility and room to fund near-term operations or development without immediate heavy refinancing. This balance-sheet conservatism lowers short-term solvency risk and supports execution of clinical or commercialization milestones over months.
Bears Say
Negative Operating And Free Cash FlowConsistent cash burn is a durable risk: negative operating and free cash flow reduce runway and force reliance on external financing or dilutive raises. Over a 2–6 month horizon, persistent negative cash conversion constrains investment in commercialization or R&D and can pressure strategic flexibility.
Sustained Net Losses / Negative Operating ProfitDespite strong gross margins, operating expenses keep the firm loss-making. Persistent negative operating profit means the business has not yet demonstrated durable ability to cover fixed costs. Achieving structural profitability will require sustained revenue recovery or material cost reductions over multiple quarters.
Revenue Deceleration After Prior RampA reversal from rapid prior growth to a TTM revenue decline signals possible demand saturation, commercialization friction, or market headwinds. This deceleration creates uncertainty about the durability of growth and the timeline to scale profits, increasing execution risk over the next several quarters.
InnoCan Pharma News
INNO FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$2.18 and its highest was C$21.00 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is C$13.27M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 25 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -C$0.296 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.296.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.296 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.88%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―